MA46235A - 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation - Google Patents

1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation

Info

Publication number
MA46235A
MA46235A MA046235A MA46235A MA46235A MA 46235 A MA46235 A MA 46235A MA 046235 A MA046235 A MA 046235A MA 46235 A MA46235 A MA 46235A MA 46235 A MA46235 A MA 46235A
Authority
MA
Morocco
Prior art keywords
ylcarboxamides
naphtyridin
aryl
substituted
ylcarboxamides substituted
Prior art date
Application number
MA046235A
Other languages
English (en)
Other versions
MA46235B1 (fr
Inventor
Arapinis Melissa Boultadakis
Markus Brechmann
Till Freudenberger
Maximilian Andreas Kullmann
Tobias Marquardt
Thomas Mondritzki
Alexander Straub
Henrik Teller
Hanna Tinel
Alexandros Vakalopoulos
Matthias Beat Wittwer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16188728.6A external-priority patent/EP3296298A1/fr
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA46235A publication Critical patent/MA46235A/fr
Publication of MA46235B1 publication Critical patent/MA46235B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA46235A 2016-09-14 2017-09-06 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation MA46235B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16188728.6A EP3296298A1 (fr) 2016-09-14 2016-09-14 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
EP16202509 2016-12-06
PCT/EP2017/072339 WO2018050510A1 (fr) 2016-09-14 2017-09-06 Amides de l'acide 1-aryl-naphthyridine-3-carboxylique substitués en position 7 et leur utilisation

Publications (2)

Publication Number Publication Date
MA46235A true MA46235A (fr) 2021-04-14
MA46235B1 MA46235B1 (fr) 2021-10-29

Family

ID=59966701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46235A MA46235B1 (fr) 2016-09-14 2017-09-06 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation

Country Status (40)

Country Link
US (3) US10927109B2 (fr)
EP (1) EP3512849B1 (fr)
JP (1) JP7295019B2 (fr)
KR (2) KR20190046851A (fr)
CN (4) CN109689656B (fr)
AU (1) AU2017326297B2 (fr)
BR (1) BR112019004982A2 (fr)
CA (1) CA3036497A1 (fr)
CL (1) CL2019000670A1 (fr)
CO (1) CO2019002361A2 (fr)
CR (1) CR20190131A (fr)
CU (1) CU24618B1 (fr)
CY (1) CY1124492T1 (fr)
DK (1) DK3512849T3 (fr)
DO (1) DOP2019000060A (fr)
EC (1) ECSP19018116A (fr)
ES (1) ES2887674T3 (fr)
GE (1) GEP20217332B (fr)
HR (1) HRP20211396T1 (fr)
HU (1) HUE056343T2 (fr)
IL (1) IL265106B (fr)
JO (1) JOP20190045A1 (fr)
LT (1) LT3512849T (fr)
MA (1) MA46235B1 (fr)
MX (1) MX2019003007A (fr)
MY (1) MY196473A (fr)
NI (1) NI201900023A (fr)
NZ (1) NZ751297A (fr)
PE (1) PE20190803A1 (fr)
PH (1) PH12019500535A1 (fr)
PL (1) PL3512849T3 (fr)
RS (1) RS62299B1 (fr)
SG (1) SG11201901973RA (fr)
SI (1) SI3512849T1 (fr)
TN (1) TN2019000083A1 (fr)
TW (1) TWI758325B (fr)
UA (1) UA125627C2 (fr)
UY (1) UY37403A (fr)
WO (1) WO2018050510A1 (fr)
ZA (1) ZA201902325B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949562B (zh) 2015-06-09 2021-07-23 拜耳制药股份公司 毒蕈碱性m2受体的正性变构调节剂
WO2018011017A1 (fr) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitués en position 7, et leur utilisation
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
JP2023521783A (ja) * 2020-04-08 2023-05-25 バイエル、アクチエンゲゼルシャフト Ｒｔ－ｐｃｒを用いたウイルス感染の迅速な検出

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
JPS60228479A (ja) 1984-04-26 1985-11-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE4301246A1 (de) 1993-01-19 1994-07-21 Bayer Ag Chinolon- und Naphthyridoncarbonsäurederivate
CA2168764C (fr) * 1993-08-13 2000-01-18 Sung June Yoon Nouveaux derives de l'acide quinolonecarboxylique
KR100516379B1 (ko) 1996-11-28 2005-09-26 와쿠나가 세이야쿠 가부시키 가이샤 신규 피리돈카르복실산 유도체 또는 그의 염 및 이를 유효 성분으로 하는 의약
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2003050107A1 (fr) 2001-12-13 2003-06-19 Wockhardt Limited Nouveaux derives d'acide piperidino-quinolone carboxylique substitue en position 7, chiraux, a action antimicrobienne a large spectre et ciblage triple, preparation, compositions contenant ces derives et leur utilisation en tant que medicaments
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
EP1650192A4 (fr) 2003-07-24 2007-03-21 Astellas Pharma Inc Derive de quinolone ou sel de ce dernier
WO2005026145A2 (fr) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Agents antibacteriens a base de quinolone
WO2005026165A1 (fr) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Agents antibacteriens a base de quinolone
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (fr) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Agents antibacteriens a la quinolone
JP2007513955A (ja) 2003-12-09 2007-05-31 バーテックス　ファーマシューティカルズ　インコーポレイテッド ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
WO2010093341A1 (fr) * 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. Dérivés de c-7 isoxazolinyl quinolone/naphthyridine convenant comme agents anti-bactériens
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
SI2512243T1 (sl) 2009-12-17 2016-07-29 Merck Sharp & Dohme Corp. Pozitivni alosterični modulatorji receptorja kinolin amid m1
EP2539326B1 (fr) 2010-02-27 2017-05-03 Bayer Intellectual Property GmbH Aryltriazolone liée à un bis-aryle et son utilisation
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (fr) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Pyrimidine et triazine condensés et leur utilisation
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (fr) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
CN103360388B (zh) 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
CN102964350A (zh) 2012-09-20 2013-03-13 杨文� 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用
CN103183676B (zh) 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
AU2015342017B2 (en) 2014-11-03 2020-02-06 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
WO2016081464A1 (fr) 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Modulateurs de transport des monocarboxylates et leurs utilisations
CN107949562B (zh) 2015-06-09 2021-07-23 拜耳制药股份公司 毒蕈碱性m2受体的正性变构调节剂
CR20170594A (es) 2015-06-09 2018-04-27 Abbvie Inc Moduladores de receptor nuclear
CN107849040B (zh) 2015-06-09 2021-04-06 肿瘤学治疗公司 三环衍生化合物、其制备方法、和含有其的药物组合物
WO2018011017A1 (fr) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitués en position 7, et leur utilisation
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
ES2887674T3 (es) 2021-12-27
GEP20217332B (en) 2021-12-10
PE20190803A1 (es) 2019-06-10
US10927109B2 (en) 2021-02-23
CN109689656B (zh) 2022-10-04
CA3036497A1 (fr) 2018-03-22
CU24618B1 (es) 2022-08-09
DK3512849T3 (da) 2021-08-16
KR20230035437A (ko) 2023-03-13
BR112019004982A2 (pt) 2019-08-20
JP2019534320A (ja) 2019-11-28
LT3512849T (lt) 2021-08-25
CL2019000670A1 (es) 2019-08-02
CY1124492T1 (el) 2022-07-22
TW201811785A (zh) 2018-04-01
DOP2019000060A (es) 2019-04-15
MA46235B1 (fr) 2021-10-29
IL265106B (en) 2022-05-01
RS62299B1 (sr) 2021-09-30
JP7295019B2 (ja) 2023-06-20
HRP20211396T1 (hr) 2021-12-10
TN2019000083A1 (en) 2020-07-15
MX2019003007A (es) 2019-07-18
US11472803B2 (en) 2022-10-18
CR20190131A (es) 2019-05-15
NZ751297A (en) 2022-12-23
MY196473A (en) 2023-04-12
SI3512849T1 (sl) 2021-10-29
UY37403A (es) 2018-04-30
HUE056343T2 (hu) 2022-02-28
TWI758325B (zh) 2022-03-21
AU2017326297A1 (en) 2019-03-28
CN115554294A (zh) 2023-01-03
US20220089591A1 (en) 2022-03-24
US20190263805A1 (en) 2019-08-29
ZA201902325B (en) 2022-03-30
US20210261541A1 (en) 2021-08-26
CU20190020A7 (es) 2019-11-04
KR20190046851A (ko) 2019-05-07
CN115477649A (zh) 2022-12-16
WO2018050510A1 (fr) 2018-03-22
ECSP19018116A (es) 2019-03-29
CN109689656A (zh) 2019-04-26
NI201900023A (es) 2019-05-23
PH12019500535A1 (en) 2019-11-04
PL3512849T3 (pl) 2021-11-29
CN115429798A (zh) 2022-12-06
UA125627C2 (uk) 2022-05-04
CO2019002361A2 (es) 2019-06-19
EP3512849B1 (fr) 2021-06-23
JOP20190045A1 (ar) 2019-03-14
AU2017326297B2 (en) 2021-07-29
EP3512849A1 (fr) 2019-07-24
SG11201901973RA (en) 2019-04-29

Similar Documents

Publication Publication Date Title
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3455978T3 (da) Multi-underbærebølge-fremgangsmåde og indretning med flere numerologier
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA43260A (fr) Liants pd1 et/ou lag3
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
DK3288865T3 (da) Opbevarings- og hentningssystem
DK3227342T3 (da) Proteinøs heterodimer og anvendelse deraf
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
AR094502A1 (es) Pirazoles sustituidos en posicion 3 y usos de los mismos
IL264813B (en) 2-oxo-imidazopyridines and their use
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA49905A (fr) Polyesteramines et polyesterquats
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA46235A (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
MA40524A (fr) Dérivés d'adrénomédulline stabilisés et leur utilisation
DK3379989T3 (da) Afstøvnings- og støvopsamlingsanordning
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
UY4713S (es) Configuración aplicada en cuchara lacre
ITUA20162241A1 (it) Dispositivo di rimagliatura e macchina comprendente detto dispositivo
MA41587A (fr) N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique
DE112017002303A5 (de) Regalbediengerät